虽然Kras G13区域是广泛研究的癌症复发区域，但其对临床作用的影响仍存在争议。通常与其他驱动因素（egfr和alk）的野生型肿瘤相关，这种突变患者的预后似乎比kras野生型队列更差。这种突变，连同影响邻近的G12位置的突变，在用第一代tki（如吉非替尼）治疗时，可能导致反应性较低的肿瘤。然而，结果与回顾性分析相矛盾，表明对eGFR抑制有更好的反应。最近的一项前瞻性II期研究（12名患者，Schiripa等人2015年）无法重现这一发现，目前正在进行另一项预期的第二阶段试验。
While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.